| Research background and objectives:The incidence,disability rates and mortality of acute cerebral infarction are high, and bring the heavy burden on families and society. Thrombolytic therapy is the exact method of evidence-based medical evidence, but thrombolytic therapy must be conducted in the therapeutic time window, and thrombolytic therapy can leade to the risk of bleeding which greatly limit its application. Human urinary kallikrein (that is youruikelin for injection, trade name:kailikang) can expand the micro-arterial cerebral ischemia in part, promote angiogenesis, protect neurological function after cerebral injury, and provide a new drug of choice of the treatment of acute cerebral infarction. In recent years, human urinary kallikrein more and more is applied in the treatment of acute cerebral infarction, but most of them are for patients within 48 hours of onset,and the research which to study the application of human urinary kallikrein on patients within 48 hours-7 days of onset for acute cerebral infarction is less.The aim of this study is to observe the efficacy and safety of human urinary kallikrein used in patients within more wider time window and the effect of long-term prognosis, and apply more reference of the application of the drug.Information and methods:To collect the patients with acute carotisal cerebral infarction who were treated in the Department of Neurology of China-Japan Union Hospital of Jilin University from February 2009 to October 2010, the 76 cases who meet the standard are randomly divided into treatment group and controlled group in accordance with the order code.The controlled group were given the conventional treatment of improve cycle, and anti-platelet gathered, and nutrition brain cell, and adjustment blood pressure, and blood glucose, and regulation electrolysis mass disorder, symptomatic treatment, (necessary Shi can, as appropriate, given mannitol, drug). The treatment group were given the human urinary kallikrein (youruikelin for injection, trade names:kailikang, Temple biochemical pharmaceutical company limited production in Guangdong) treatment on the basis of the conventional treatment treatment,youruikelin 0.15PNA U was joined in the 250ml saline solution,1 time/day, Intravenous drip,the treatment course is 14 days,â‘¡to evaluate the effct of neurological deficits and clinical efficacy before and after the treatment using United States national institutes of neurological function defect score (NIHSS), to evaluate the patients'quality of daily life (ADL) using the Barthel index (BI) and the ADL score for 60 days after treatment. To monitor the patients'blood pressure during the treatment,and to monitor the patients'blood tests,urine tes,liver and kidney function,blood glucose,blood lipid,coagulation test before and after the treatment.Results:All patients completed the treatment of 14 days,(1) NIHSS score of the patients in both groups are lower (P<0.05),ADL score are increased (P<0.05), (2) NIHSS score,the ADL score and total effective rate of the treatment group significantly better than the control group'(P<0.05).(3)ADL score of 60 days after treatment is significantly different between the two groups(P<0.05).Conclusions:1. The application of human urinary kallikrein can significantly improve neurological function in patients with acute carotisal cerebral infarction, with good clinical efficacy-. long-term prognosis and security.2. The time window of th treatment of human urinary kallikrein applied in the patients with acute cerebral infarction is wider, the application of human urinary kallikrein on patients within 48 hours-7 days of onset is also able to significantly improve neurologic impairment in patients with good clinical efficacy and long-term prognosis. |
PDF Full Text Request